Higher concentrations of GD progression markers, such as lysoGb-1 and chitotriosidase, along with lower platelet counts in patients with nodular goiter compared to those without nodular goiter, may hypothetically suggest an increased risk of thyroid nodule formation in patients with more advanced or less responsive to primary disease treatment [21]. This evidence concerns the gene CHIT1 and thyroid nodule.